表紙:中国の医薬品開発業務受託機関 (CRO) 産業の分析 (2020年~2026年)
市場調査レポート
商品コード
973124

中国の医薬品開発業務受託機関 (CRO) 産業の分析 (2020年~2026年)

China Contract Research Organization (CRO) Industry Report, 2020-2026

出版日: | 発行: ResearchInChina | ページ情報: 英文 202 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
中国の医薬品開発業務受託機関 (CRO) 産業の分析 (2020年~2026年)
出版日: 2020年11月17日
発行: ResearchInChina
ページ情報: 英文 202 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

中国は医薬品の研究開発コストに関して先進国に対する高い競争力を有し、多くの国際的な大手製薬企業を魅了し、CRO (開発業務受託機関) 産業を発展させてきました。2020年に、中国のCRO業界は年率10.1%の速度で成長し、816億人民元の規模に達する見通しです。外資系企業のみならず、昨今では国内系企業も大きく成長しています。近年の業界の主な動きとして、企業合併・買収 (M&A) の増加や大手企業の相次ぐ上場、垂直統合の進展などが挙げられます。

当レポートでは、中国の医薬品開発業務受託機関 (CRO) 産業について分析し、世界市場の沿革・構造・動向や、中国国内の発展環境・沿革、業界の基本構造や背景事情、全体的な市場規模の動向見通し、競合パターン、昨今の発展動向、主な国内系/外資系企業のプロファイル (業績、事業構造、戦略展開状況ほか) などを調査しております。

目次

第1章 医薬品のアウトソーシングの概要

  • 定義
  • 分類
  • CRO (医薬品開発業務受託機関)

第2章 世界のCRO産業の発展動向

  • 産業発展の歴史
  • 産業発展の背景事情
    • 製薬業界の規模
    • 製薬企業の動向
    • 資金調達
    • 医薬品の研究開発 (R&D)
  • 市場規模
  • 競合情勢

第3章 中国のCRO産業

  • 発展環境
    • 規制
    • 政策環境
    • 業界環境
  • 現状
  • 市場規模
  • 競合情勢
  • 発展動向
    • 研究開発費の負担増大:製薬企業は新薬開発のCRO企業への依存を強める
    • 有利な政策と資本投入:国内系企業の発展の促進要因
    • 明るい発展見通しが、多くの企業をCRO産業へと惹きつける
    • 業界の垂直統合の進展
    • 企業合併・買収 (M&A):CRO企業の主要な拡大手段となる可能性
    • 一貫性評価の包括的実施が、CRO業界に発展開発の機会をもたらす
    • 必要な企業規模や業界の集中度が徐々に上昇
    • 特定分野への特化・強化の動きがより明確となる

第4章 主要な国内系企業

  • Wuxi AppTec
  • Hangzhou Tigermed
  • Guangzhou Boji Pharmaceutical
  • Shanghai Meidicilon Inc.
  • Porton Fine Chemicals
  • Joinn Laboratories
  • Pharmaron
  • Obio Technology (Shanghai)
  • Nanjing Huawe Medicine Technology Group Co., Ltd.
  • Shanghai ChemPartner
  • HitGen Inc.
  • BioDuro
  • VIVA Biotech

第5章 主要な外資系企業

  • LabCorp
  • IQVIA
  • Parexel
  • Charles River
  • PPD
  • Syneos Health
  • PRA
  • ICON
目次

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the proliferating expenses for pharmaceutical R&D. In 2020, the world CRO market is expected to worth $69.9 billion with a year-on-year spike of 9%.

Competition ever pricks up among at least 1,100 CRO players worldwide led by LabCorp, IQVIA, Syneos, Parexel, PRA, PPD, and Charles River. In 2019, IQVIA, LabCorp and Syneos were the three leaders sweeping a combined market share of 21.5%.

China's great competitive edge over the developed countries in pharmaceutical R&D cost has allured many world-renowned pharmaceutical corporations and boosted the country's CRO industry. With speedy development over a decade, China has been an important CRO market whose market size in 2020 will soar 10.1% on an annualized basis and reach RMB81.6 billion.

In addition to multinational giants represented by IQVIA, LabCorp, Parexel, etc., China also sees local CRO leaders including Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed, and Joinn Laboratories, where Wuxi AppTec with the strongest R&D strength as one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, not only runs the China's largest small-molecule pharmaceutical R&D service business but leads the way in global market. It enjoyed a virtually 12.3% (up 1.8 percentage points over the prior year) of the world's CRO market in 2019.

China's CRO industry will be heading towards:

  • 1) Mergers and acquisitions will still prevail for an industry reshuffle: Seen from the development course of multinational CRO companies, giants expand their business and sharpen edges through M&As, so do the Chinese CRO peers in recent year. In September 2020, Asymchem acquired the CRO company GoalGen for RMB30 million.
  • 2) Chinese CRO companies have landed in the capital market: WuXi AppTec and Pharmaron were listed on the A-share and H-share markets successively. In 2019, Viva Biotech went public on the Hong Kong Stock Exchange. In 2020, HitGen was listed on the A-share market.
  • 3) The industry gears toward vertical integration: Wuxi AppTec, for example, is able to provide customers with integrated new drug R&D and production services, which can help customers save plenty of time and costs as well as improve R&D and production efficiency. Noticeably, the players like Pharmaron, Boji Medical Biotechnological, Porton Pharma Solutions, and Shanghai ChemPartner are expanding to CMO/CDMO.

“China Contract Research Organization (CRO) Industry Report, 2020-2026” highlights:

  • Global CRO industry (development history/environment, market size, competitive landscape, etc.);
  • China CRO industry (development environment, status quo, market size, competition pattern, development trends, etc.);
  • 13 Chinese and 8 foreign companies (revenue, business structure, CRO business, etc.)

Table of Contents

1. Overview of Pharmaceutical Outsourcing

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 CRO

2. Evolution of Global CRO Industry

  • 2.1 Development History
  • 2.2 Development Background
    • 2.2.1 Pharmaceutical Industry Size
    • 2.2.2 Pharmaceutical Companies Development
    • 2.2.3 Financing
    • 2.2.4 Pharmaceutical R&D
  • 2.3 Market Size
  • 2.4 Competitive Landscape

3. CRO Industry in China

  • 3.1 Development Environment
    • 3.1.1 Regulation
    • 3.1.2 Policy Environment
    • 3.1.3 Industry Environment
  • 3.2 Status Quo
  • 3.3 Market Size
  • 3.4 Competitive Landscape
  • 3.5 Development Trend
    • 3.5.1 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
    • 3.5.2 Favorable policies and capital promote the development of local Chinese companies
    • 3.5.3 Good Prospects Attract the Enterprises' Access into CRO Industry
    • 3.5.4 The Industry Heads toward Vertical Integration
    • 3.5.5 M&A May Become the Main Way for CRO Companies to Expand
    • 3.5.6 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry
    • 3.5.7 Industry threshold and concentration degree rises gradually
    • 3.5.8 Specialization and characterization are becoming ever more obvious

4. Major Chinese Companies

  • 4.1 Wuxi AppTec
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 Major Clients
    • 4.1.6 R&D Investment
    • 4.1.7 CRO Business
    • 4.1.8 Development Strategy
  • 4.2 Hangzhou Tigermed
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Investment
    • 4.2.6 Development Strategy
  • 4.3 Guangzhou Boji Pharmaceutical
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Investment
    • 4.3.6 Development Strategy
  • 4.4 Shanghai Meidicilon Inc.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Investment
    • 4.4.6 Major Clients
    • 4.4.7 Development Strategy
  • 4.5 Porton Fine Chemicals
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D Investment
    • 4.5.6 Major Clients
    • 4.5.7 Development Strategy
  • 4.6 Joinn Laboratories
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Investment
    • 4.6.6 Major Clients
    • 4.6.7 Development Strategy
  • 4.7 Pharmaron
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Investment
    • 4.7.6 Major Clients
    • 4.7.7 Development Strategy
  • 4.8 Obio Technology (Shanghai)
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Investment
    • 4.8.6 Major Clients
    • 4.8.7 Development Strategy
  • 4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Major Clients
    • 4.9.4 Main Business
    • 4.9.5 Development Strategy
  • 4.10 Shanghai ChemPartner
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Gross Margin
    • 4.10.5 Main Business
  • 4.11 HitGen Inc.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Revenue Structure
    • 4.11.4 Gross Margin
    • 4.11.5 R&D Investment
    • 4.11.6 Major Clients
  • 4.12 BioDuro
    • 4.12.1 Profile
    • 4.12.2 Development Course
    • 4.12.3 R&D Center
    • 4.12.4 Development Dynamics
  • 4.13 VIVA Biotech
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 R&D Investment

5 Major Foreign Companies

  • 5.1 LabCorp
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 Revenue Structure
    • 5.1.4 CRO Business
    • 5.1.5 Development in China
  • 5.2 IQVIA
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 Revenue Structure
    • 5.2.4 Development Strategy
    • 5.2.5 Development in China
  • 5.3 Parexel
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 Revenue Structure
    • 5.3.4 Dynamics
    • 5.3.5 Development in China
  • 5.4 Charles River
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 Revenue Structure
    • 5.4.4 Development in China
  • 5.5 PPD
    • 5.5.1 Profile
    • 5.5.2 Operation
    • 5.5.3 Revenue Structure
    • 5.5.4 Development in China
    • 5.5.5 Excel PharmaStudies
  • 5.6 Syneos Health
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 Revenue Structure
    • 5.6.4 CRO Business
    • 5.6.5 Development in China
  • 5.7 PRA
    • 5.7.1 Profile
    • 5.7.2 Operation
    • 5.7.3 Revenue Structure
    • 5.7.4 Development in China
  • 5.8 ICON
    • 5.8.1 Profile
    • 5.8.2 Operation
    • 5.8.3 Revenue Structure
    • 5.8.4 Development in China